跳到正文
PharmaTimes· John Pinching·· 19 天前AI 评分28

Exogenus牵头1300万欧元欧盟项目,推进EXO-101分泌组疗法用于骨关节炎

Exogenus leads €13 million EU project for secretome therapy

AI 导读

Exogenus Therapeutics牵头ExoCordOA联盟启动为期五年、1300万欧元的Horizon Europe项目,推动胞外囊泡富集分泌组疗法走向临床,首个适应症为骨关节炎。项目将支持其先导候选药EXO-101的1期和2期临床开发,并解决制造、质量控制与监管瓶颈。联盟由十家机构组成,包括Lonza、Anthony Nolan和乌得勒支大学等。

正文 · 原文

Consortium to advance EXO‑101 for osteoarthritis

The ExoCordOA consortium has launched a five‑year, €13 million Horizon Europe project to advance extracellular vesicle‑enriched secretome therapies towards clinical use, beginning with osteoarthritis.

Led by Exogenus Therapeutics, the initiative brings together ten organisations spanning biotechnology, clinical development, regulation, GMP manufacturing, imaging, academia and healthcare.

The consortium will combine these capabilities to support development of a new secretome‑based medicine for osteoarthritis and strengthen Europe’s position in regenerative and anti‑inflammatory therapeutics. A central objective is to progress Exogenus’ lead candidate, EXO‑101, towards clinical validation as a potential disease‑modifying treatment.

The programme will back the candidate’s phase 1 and 2 clinical development while addressing scientific, manufacturing, quality‑control and regulatory challenges that currently limit clinical translation of extracellular vesicle and secretome therapies.

It aims to resolve systemic bottlenecks by supporting more standardised approaches, robust analytical and potency assessment methods and a clearer regulatory pathway for future secretome‑based medicines.

Joana Correia, PhD, Co‑Founder and Chief Executive Officer of Exogenus Therapeutics, said: “ExoCordOA brings together the expertise needed not only to advance EXO-101 towards clinical validation in osteoarthritis, but also to tackle barriers affecting the wider secretome therapeutics field.”

She added: “As project coordinator, Exogenus is proud to lead this collaborative European effort to establish stronger scientific, manufacturing and regulatory foundations for a new generation of regenerative medicines.”

The consortium includes Lonza, Anthony Nolan, Eliquent Life Sciences, iLoF, Utrecht University, University Medical Center Utrecht, Maastricht University Medical Center+, Image Analysis Group and ReumaNederland.

来源:PharmaTimes · pharmatimes.com